JWH-193
From Wikipedia, the free encyclopedia
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
|
Systematic (IUPAC) name: (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethanone
|
|
| CAS Number | 133438-58-1  |
| PubChem (CID) | 10250276 |
| ChemSpider | 8425762 |
| UNII | WB1TIJ1IO9 |
| Chemical and physical data | |
| Formula | C26H26N2O2 |
| Molar mass | 398.496 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (verify) | |
JWH-193 is a drug from the aminoalkylindole family which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB1 receptor of 6nM, binding around seven times more tightly than the parent compound JWH-200,[1] though with closer to twice the potency of JWH-200 in activity tests. A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.[2][3]
See also[edit]
References[edit]
- ^ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
- ^ Eissenstat MA, et al. (August 1995). "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics". Journal of Medicinal Chemistry. 38 (16): 3094–105. doi:10.1021/jm00016a013. PMID 7636873.
- ^ Shim JY, et al. (November 1998). "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis". Journal of Medicinal Chemistry. 41 (23): 4521–32. doi:10.1021/jm980305c. PMID 9804691.
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
